June 17, 2021 – 12:53 pm
#AstraZeneca #Vaccination campaign #coronavac #coronavirus #Covid-19 #Pandemia #vaccination reactions #Post-vaccination reactions #Health Ceará #Sesa #vaccinations
Suzana Mont’Alverne – Ascom Sesa – Text
Tiago Stille – Photo
The population must inform the health authorities of any symptoms that appear within 30 days after the application of the vaccine
As the Covid-19 vaccination campaign advances, so do reports of adverse events following immunization. The Department of Health of Ceará (Sesa) therefore guides the population to seek health services and communicate to responsible bodies, such as municipal health departments, about reactions after the application of the vaccine. All post-vaccination adverse events are reported to the Ministry of Health (MS) reporting system, the e-SUS.
According to the technique of the Sesa Immunization Cell, Surama Elarrat, it is recommended to report any symptoms that appear within 30 days after immunization. “The most frequent adverse events reported appeared in the first 24 hours after vaccination and are commonly benign, self-limited and improve within a few days or within 72 hours”, he explains.
In Ceará, from January 24 to May 28, 1,401 suspected cases of Post-Vaccination Adverse Events were reported in the e-SUS, with 772 for the immunizing agent CoronaVac/Sinovac/Butantan, 623 from Oxford/AstraZeneca/Fiocruz and six from Pfizer. “In relation to Sinovac’s, 215 cases evaluated were confirmed to be related to the vaccine and 348 events were related to the application of the AstraZeneca vaccine. All reactions attributed to the immunization were not serious”, analyzes Surama.
Hypersensitivity to the active ingredient or to another component is a contraindication to any vaccination and does not change to the immunizing agent against Covid-19. “AstraZeneca/Fiocruz is contraindicated for those who have already suffered venous and/or arterial thrombosis associated with thrombocytopenia,” says Surama. So far, in Ceará, there has been no notification of a case of Thrombosis Syndrome with Thrombocytopenia (TTS).
“The recommendation not to administer the second dose of the immunizing agent Oxford/AstraZeneca/Fiocruz is restricted to cases of greater venous or arterial thrombosis, associated with thrombocytopenia, after the first dose of the respective vaccine. The National Immunization Program also recommends that an alternative vaccine, which does not have a non-replicating adenovirus viral vector platform, be used in patients with a previous picture of Heparin-Induced Thrombocytopenia (HIT), until it is properly evaluated whether these individuals are or not at greater risk of having an episode of TTS”, complements the technique.
The National Plan for the Operationalization of Vaccination against Covid-19 also defines that people with a personal history of thrombosis (not associated with HIT) or thrombophilia, regardless of the use of coagulants, have no contraindication to the use of the Oxford/AstraZeneca vaccine /Fiocruz or another vaccine that uses a non-replicating viral vector platform.
Sesa alerts health workers to the signs and symptoms of Thrombosis Syndrome with Thrombocytopenia and recommendations for appropriate management, as detailed in Technical Note No. 441 / 2021. Suspected cases of the Syndrome must be notified in the e-SUS.
Pregnant and postpartum women
By indication of the Ministry of Health, there is contraindication with AstraZeneca’s immunizing agent for pregnant and postpartum women. “In Ceará, the recommendation for vaccination of pregnant and postpartum women with comorbidities with the other Covid-19 vaccines in use, with those of Sinovac/Butantan and Pfizer/Wyeth is maintained”, underlines the Sesa technique.
Surama stresses that “pregnant women and postpartum women (including those without additional risk factors) who have already received the first dose of the Oxford/AstraZeneca/Fiocruz vaccine should wait for the end of the gestational and postpartum period (up to 45 days after delivery) for administration of Monday dose of the vaccine”.
People with a post-vaccine reaction can be treated through the Coronavirus Service, via WhatsApp, at (85) 98439 0647.
Notifying units with questions should contact the Center for Strategic Information on Health Surveillance (Cievs) at: (85) 3101.4860, 3101.5215 and 98724.0455; and by emails: [email protected] e [email protected].